IONS analyst estimates

Ionis Pharmaceuticals (IONS) analyst ratings, the average price target and its range, and every firm's latest call.

IONS analyst ratings and price targets

DateFirmCallTarget
Oct 21, 2026BMO Capital5-star BMO analyst upgrades Ionis ahead of Q3 report$66.00
Oct 20, 2026Raymond JamesIonis Pharmaceuticals price target lowered to $79 from $84 at Raymond James$79.00
Oct 15, 2026UBSIonis Pharmaceuticals upgraded to Buy from Neutral at UBS$88.00
Sep 24, 2026OppenheimerOppenheimer Reiterates Outperform Rating on Ionis Pharmaceuticals (IONS)$85.00
Sep 15, 2026GuggenheimIonis Pharmaceuticals (IONS) PT Lowered to $80 at Guggenheim$80.00
Sep 9, 2026BarclaysIonis Pharmaceuticals price target lowered to $85 from $90 at Barclays$85.00
Sep 8, 2026Goldman SachsIonis Pharmaceuticals price target lowered to $56 from $69 at Goldman Sachs$56.00
Sep 8, 2026BMO CapitalIonis Pharmaceuticals price target lowered to $54 from $61 at BMO Capital$54.00
Sep 8, 2026Canaccord GenuityIonis Pharmaceuticals price target lowered to $85 from $95 at Canaccord$85.00
Sep 8, 2026Morgan StanleyIonis Pharmaceuticals price target lowered to $104 from $110 at Morgan Stanley$104.00
Sep 8, 2026Raymond JamesIonis Pharmaceuticals price target lowered to $84 from $87 at Raymond James$84.00
Sep 4, 2026BMO CapitalIonis Pharmaceuticals price target raised to $61 from $60 at BMO Capital$61.00
Jul 30, 2026H.C. WainwrightIonis Pharmaceuticals (IONS) PT Lowered to $115 at H.C. Wainwright$115.00
Jul 29, 2026Goldman SachsIonis Pharmaceuticals price target raised to $69 from $66 at Goldman Sachs$69.00
Jul 21, 2026GuggenheimIonis Pharmaceuticals (IONS) PT Lowered to $89 at Guggenheim$89.00

Updated 2026-11-02 23:10 UTC